Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ustekinumab · 1 trial · 1 indication
The percentage of patients who achieved ASAS40 response defined as an improvement of ≥40% and ≥2 points in at least 3 out of four following domains (and no worsening in remaining domain): * Patient global * Pain * Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI) * Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)
| Arm | Type | Description |
|---|---|---|
| Ustekinumab | EXPERIMENTAL | Ustekinumab 90 mg subcutaneously at week 0, 4 and 16 |
| Name | Type | Description |
|---|---|---|
| Ustekinumab | DRUG | Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16 |
Inclusion Criteria: 1. Age of ≥18 years. 2. Definite diagnosis of AS according to the modified New York criteria. 3. History of an inadequate response to ≥2 NSAIDs taken for at least 2 weeks each or NSAIDs intolerance/contraindication. 4. Active disease as defined by a BASDAI value of ≥4 at screeni...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | vilamakitug |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Upadacitinib |
| Novartis AG Sponsored ADR | NVS | 1 | - | Secukinumab |
| Pfizer Inc. | PFE | 1 | - | Tofacitinib |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |